Our recent study demonstrated that the targeting of METTL3 by METTL3-sgRNA or chemical METTL3 inhibitor STM2457 could potentiate the effect of anti-PD1 treatment in different mouse CRC syngeneic models [77]. This evidence concerns the gene METTL3 and colorectal carcinoma.